Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 285 institutions reported holding it in 13F filings for Q3 2026, worth $8.99B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Feb 19, 2026 | Jan 13, 2025 | Feb 29, 2024 | Mar 2, 2023 | Feb 9, 2022 |
| Revenue | $0 | $0 | $886.0K | $2.33M | $18.7M |
| Operating expenses | $209.6M | $208.6M | $243.2M | $87.1M | $84.4M |
| Research and development | $171.7M | $162.8M | $89.5M | $58.6M | $57.1M |
| Selling, general and administrative | $47.9M | $45.8M | $39.9M | $28.5M | $27.3M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M |
| Income tax | -$15.0K | $51.0K | -$26.0K | -$136.0K | $141.0K |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M |
| EPS, basic | – | – | $13.76 | $-0.99 | – |
| EPS, diluted | – | – | $13.76 | $-0.99 | – |
| Weighted shares, basic | – | – | 6.90M | 84.3M | – |
| Weighted shares, diluted | – | – | 6.90M | 84.3M | – |
| Margins and growth | |||||
| Operating margin | – | – | -27348.0% | -3640.2% | -350.3% |
| Net margin | – | – | -38238.1% | -3598.8% | -351.1% |
| Revenue growth, year over year | – | −100.0% | −62.0% | −87.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023! | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Feb 19, 2026 | Jan 13, 2025 | Feb 29, 2024 | Mar 2, 2023 | Feb 9, 2022 |
| Cash and equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M |
| Total current assets | $777.8M | $608.5M | $341.5M | $62.3M | $98.9M |
| Property, plant and equipment | – | – | $0 | $3.22M | $4.55M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M |
| Accounts payable | – | – | – | $677.0K | $3.32M |
| Total current liabilities | $58.7M | $54.1M | $32.0M | $14.7M | $20.1M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M |
| Shareholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Feb 19, 2026 | Jan 13, 2025 | Feb 29, 2024 | Mar 2, 2023 | Feb 9, 2022 |
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M |
| Capital expenditures | – | $0 | $0 | $38.0K | $573.0K |
| Free cash flow | – | -$157.4M | -$99.9M | -$80.2M | -$54.3M |
| Depreciation and amortization | $0 | $0 | $744.0K | $1.57M | $1.58M |
| Stock-based compensation | $37.6M | $44.8M | $25.7M | $7.11M | $8.04M |
| Investing cash flow | -$143.5M | -$353.3M | -$108.4M | $57.0M | -$22.6M |
| Financing cash flow | $309.0M | $410.9M | $361.1M | $42.7M | $1.39M |
| Net change in cash | -$3.70M | -$99.8M | $152.8M | $19.4M | -$75.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 2897.9% | 305.3% | 42.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 95.0M | +22.4% | SEC |
| Jul 28, 2026 | 88.2M | +46.0% | SEC |
| Apr 28, 2026 | 86.8M | +43.9% | SEC |
| Feb 12, 2026 | 78.5M | +30.3% | SEC |
| Oct 29, 2025 | 77.6M | +50.9% | SEC |
| Jul 31, 2025 | 60.4M | +18.9% | SEC |
| May 2, 2025 | 60.4M | +49.8% | SEC |
| Feb 19, 2025 | 60.3M | +66.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-25 in Q3 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.